The Vera Rubin Observatory (VRO) hasn’t yet begun it’s much-anticipated Legacy Survey of Space and Time. But it saw its first light in June 2025, when it captured its Virgo First Look images as part of commisioning its main camera. Those…
Blog
-
Australia’s insurance market softens as competition intensifies
The property sector is seeing an influx of local and international capacity.
Australia’s insurance market is entering a softening phase as competition increases, particularly in property and financial lines, according to WTW’s latest Global…
Continue Reading
-
Tim Cook didn't have much to say about reports of low iPhone Air sales – AppleInsider
- Tim Cook didn’t have much to say about reports of low iPhone Air sales AppleInsider
- New report claims Apple hasn’t cut iPhone Air production – GSMArena.com news GSMArena.com
- Apple’s iPhone Air doesn’t look like a bestseller. It might not matter
Continue Reading
-
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
- Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]SOURCE Nektar Therapeutics
Continue Reading
-
Eugenie, Beatrice to keep royal titles
Prince Andrew will soon simply be known as Andrew Mountbatten Windsor after the process to strip the disgraced brother of King Charles III of all of his royal titles began today, but his daughters will keep theirs.
The formal process to remove…
Continue Reading
-
Your DNA could reveal a hidden heart attack risk: Scientists uncover the genetic code behind high cholesterol |
In a major scientific breakthrough, researchers have created the first comprehensive genetic resource to identify people at risk of dangerously high cholesterol and heart disease, even if their cholesterol levels appear normal. The…
Continue Reading
-
Chronic Spontaneous Urticaria Linked to Increased Heart Disease Risk
Individuals diagnosed with
chronic spontaneous urticaria (CSU) are at a moderately increased risk of multiple cardiovascular diseases, with conduction disorders showing the most consistent and significant association, according to a study…Continue Reading
-
The effect of strabismus surgery on the quality of life in children and adolescents | BMC Ophthalmology
In our study, significant improvements were observed in emotional, social, and school-related domains of HRQOL among the cases, whereas physical functionality remained unchanged. The HRQOL quality of life scale can be used to evaluate the effects…
Continue Reading
-
Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control
Researchers at the University of Chicago have developed a comprehensive mathematical model that predicts diabetes complications up to 15 years in advance, offering clinicians a powerful new tool to understand how early treatment decisions shape…
Continue Reading
-
Wave of RSV, particularly dangerous for babies, washing over U.S.
A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States — sending greater numbers of babies and toddlers to the hospital, recent data show.
The onset of RSV comes as the country heads into the…
Continue Reading